tariquidar has been researched along with n-demethylloperamide in 5 studies
| Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) | Studies (n-demethylloperamide) | Trials (n-demethylloperamide) | Recent Studies (post-2010) (n-demethylloperamide) |
|---|---|---|---|---|---|
| 210 | 16 | 138 | 22 | 3 | 13 |
| Protein | Taxonomy | tariquidar (IC50) | n-demethylloperamide (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.245 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.483 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herscovitch, P; Innis, RB; Kimura, N; Kreisl, WC; Liow, JS; Morse, CL; Pike, VW; Seneca, N; Zoghbi, SS | 1 |
| Brimacombe, KR; Gottesman, MM; Hall, MD; Halldin, C; Innis, RB; Kannan, P; Kreisl, WC; Liow, JS; Pike, VW; Telu, S; Zhang, Y; Zoghbi, SS | 1 |
| Amano, N; Hirabayashi, H; Moriwaki, T; Sugimoto, H | 1 |
| Bae, SA; Chong, DJ; Easwaramoorthy, B; Farwell, MD; Ichise, M; Iida, Y | 1 |
| Bhatia, R; Innis, RB; Kreisl, WC; Morse, CL; Pike, VW; Shetty, HU; Woock, AE; Zoghbi, SS | 1 |
2 trial(s) available for tariquidar and n-demethylloperamide
| Article | Year |
|---|---|
P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Blood-Brain Barrier; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kinetics; Loperamide; Magnetic Resonance Imaging; Male; Positron-Emission Tomography; Quinolines; Radioactive Tracers | 2010 |
Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Topics: Administration, Intravenous; Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Dose-Response Relationship, Drug; Female; Humans; Loperamide; Male; Permeability; Positron-Emission Tomography; Quinolines; Safety | 2015 |
3 other study(ies) available for tariquidar and n-demethylloperamide
| Article | Year |
|---|---|
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line, Tumor; Humans; Isotope Labeling; Loperamide; Lysosomes; Mice; Positron-Emission Tomography; Quinolines; Radiography; Tritium | 2011 |
Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Drug Interactions; Humans; LLC-PK1 Cells; Loperamide; Quinolines; Swine; Verapamil | 2013 |
Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Brain; Cyclosporine; Kinetics; Loperamide; Male; Positron-Emission Tomography; Quinolines; Rats; Rats, Sprague-Dawley | 2013 |